CTLA4 and cancer: Nevertheless, cancer immunotherapies such as CTLA-4 and PD-1 inhibitors are effective only in a minority of patients [27, 28], therefore, there is still an urgent need for strategies to expand the population that can benefit from these novel therapies [29, 30].